BioArctic : Marketing Authorization Application For Lecanemab Submitted In Great Britain
22/5 05:26
(RTTNews) - BioArctic AB's partner Eisai said that they have submitted a Marketing Authorisation Application for lecanemab, an investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer's disease (AD) with confirmed amyloid pathology in the...